Britain has identified 30 cases of rare blood clot events following the use of the AstraZeneca vaccine — 25 more than initially reported.
The Medicines and Healthcare products Regulatory Agency (MHRA) maintained that the benefits of the vaccine in the prevention of Covid-19 far outweighed any potential risk of blood clots.
Yesterday it put the total count of reported cases of the extremely rare brain clotting ailment, cerebral venous sinus thrombosis, at 22 and the number of reports of other clotting events associated with low blood platelets at eight.
